Contraception

38
Pipeline Programs
9
Companies
50
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
6
0
19
7
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
35 programs
2
6
10
1
Long Acting Reversible ContraceptionPhase 4
BAY86-5016, SH P00331FPhase 31 trial
BAY86-5300Phase 31 trial
ESS310Phase 31 trial
Gestodene/EEPhase 31 trial
+30 more programs
Active Trials
NCT03127722Completed990Est. Dec 2024
NCT01331655Withdrawn0Est. Nov 2014
NCT01198444Completed11,884Est. May 2008
+47 more trials
M&
Merck & Co.RAHWAY, NJ
9 programs
1
4
Etonogestrel contraceptive implantPhase 41 trial
Etonogestrel contraceptive implantPhase 41 trial
Long Acting Reversible ContraceptionPhase 41 trial
Rifampin 600 MGPhase 41 trial
ENG implantPhase 11 trial
+4 more programs
Active Trials
NCT03058978Completed117Est. Dec 2021
NCT02037919Completed148Est. May 2017
NCT03559634Completed55Est. Jan 2023
+6 more trials
Pfizer
PfizerNEW YORK, NY
5 programs
1
2
Sayana PressPhase 41 trial
Subcutaneous depot medroxyprogesterone acetatePhase 41 trial
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPhase 31 trial
Medroxyprogesterone 17-AcetateN/A1 trial
Pharmacist-administeredN/A1 trial
Active Trials
NCT01019369Completed132Est. Nov 2012
NCT00775047Completed50Est. Jul 2008
NCT00245921Completed2,000Est. Oct 2005
+2 more trials
Teva
TevaIsrael - Petach Tikva
6 programs
2
3
DR-1011Phase 31 trial
DR-102Phase 33 trials
Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tabletsPhase 31 trial
TV-46046Phase 11 trial
TV-46046Phase 11 trial
+1 more programs
Active Trials
NCT02024672Completed96Est. Sep 2017
NCT04682353Completed60Est. Jan 2023
NCT03700658Completed27Est. Oct 2020
+5 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
1
1
norelgestromin + ethinyl estradiolPhase 34 trials
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EEPhase 11 trial
Active Trials
NCT00258076Completed53Est. Sep 2004
NCT00261482Completed778Est. Dec 2004
NCT00236769Completed1,751Est. Oct 1999
+2 more trials
AT
Agile TherapeuticsNJ - Princeton
2 programs
2
AG200-15Phase 31 trial
AG200-15Phase 31 trial
Active Trials
NCT01236768Completed407Est. Jun 2011
NCT01181479Completed1,504Est. Mar 2012
Evofem Biosciences
Evofem BiosciencesCA - San Diego
2 programs
2
AMPHORAPhase 31 trial
ConceptrolPhase 31 trial
Active Trials
NCT03243305CompletedEst. Nov 2018
NCT01306331CompletedEst. Jun 2014
Femasys
FemasysSUWANEE, GA
4 programs
FemBlocN/A1 trial
FemBlocN/A1 trial
FemBlocN/A1 trial
FemBloc® Permanent Contraceptive SystemN/A1 trial
Active Trials
NCT04273594Active Not Recruiting45Est. Apr 2027
NCT03433911Completed240Est. Feb 2025
NCT05977751Recruiting573Est. Jun 2031
+1 more trials
Gedeon Richter
Gedeon RichterHungary - Budapest
1 program
International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety StudyN/A1 trial
Active Trials
NCT06028555Recruiting101,000Est. Oct 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Rifampin 600 MG
Merck & Co.Etonogestrel contraceptive implant
PfizerSayana Press
Merck & Co.Etonogestrel contraceptive implant
Merck & Co.Long Acting Reversible Contraception
PfizerSubcutaneous depot medroxyprogesterone acetate
Johnson & Johnsonnorelgestromin + ethinyl estradiol
Evofem BiosciencesAMPHORA
BayerESS310
BayerEE/DRSP
BayerSkyla
BayerLNG-IUS
Evofem BiosciencesConceptrol
BayerBAY86-5300
Agile TherapeuticsAG200-15

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 30,854 patients across 50 trials

NCT04463680Merck & Co.Rifampin 600 MG

Rifampin and the Contraceptive Implant

Start: Sep 2020Est. completion: Feb 202224 patients
Phase 4Completed
NCT04423055Merck & Co.Etonogestrel contraceptive implant

Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive

Start: Aug 2020Est. completion: Apr 2024120 patients
Phase 4Completed
NCT03034057PfizerSayana Press

Sayana Press UK Self-Injection Study

Start: Aug 2017Est. completion: Dec 2018169 patients
Phase 4Completed
NCT02852265Merck & Co.Etonogestrel contraceptive implant

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

Start: Sep 2016Est. completion: Jul 201720 patients
Phase 4Completed
NCT02735551Merck & Co.Long Acting Reversible Contraception

LARC Forward Contraceptive Counseling at MHCC

Start: Apr 2016Est. completion: Mar 20173 patients
Phase 4Terminated
NCT02509767PfizerSubcutaneous depot medroxyprogesterone acetate

Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood

Start: Aug 2015Est. completion: Dec 2017401 patients
Phase 4Completed
NCT00261482Johnson & Johnsonnorelgestromin + ethinyl estradiol

Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.

Start: Jul 2003Est. completion: Dec 2004778 patients
Phase 4Completed
NCT03243305Evofem BiosciencesAMPHORA

AMP002 Phase III Contraceptive Study

Start: Jul 2017Est. completion: Nov 2018
Phase 3Completed
NCT02064413BayerESS310

Essure (Model ESS310) Placement Rate Study

Start: Mar 2014Est. completion: Nov 2014134 patients
Phase 3Completed
NCT01331655BayerEE/DRSP

Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America

Start: Apr 2013Est. completion: Nov 20140
Phase 3Withdrawn
NCT01434160BayerSkyla

LCS12 Adolescent Study

Start: Sep 2011Est. completion: May 2015304 patients
Phase 3Completed
NCT01397097BayerLNG-IUS

LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

Start: Sep 2011Est. completion: Apr 2015766 patients
Phase 3Completed
NCT01306331Evofem BiosciencesConceptrol

Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel

Start: Apr 2011Est. completion: Jun 2014
Phase 3Completed
NCT01257984BayerBAY86-5300

Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function

Start: Dec 2010Est. completion: Sep 2012508 patients
Phase 3Completed
NCT01236768Agile TherapeuticsAG200-15

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

Start: Oct 2010Est. completion: Jun 2011407 patients
Phase 3Completed
NCT01181479Agile TherapeuticsAG200-15

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Start: Aug 2010Est. completion: Mar 20121,504 patients
Phase 3Completed
NCT01178125TevaDR-102

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

Start: Aug 2010Est. completion: Jan 20132,858 patients
Phase 3Completed
NCT00920985BayerGestodene/EE

US Cycle Control and Blood Pressure Study

Start: Jun 2009Est. completion: Sep 2010346 patients
Phase 3Completed
NCT00984789BayerEthinylestradiol/Gestodene

Birth Control Patch Study

Start: May 2009Est. completion: Sep 2010393 patients
Phase 3Completed
NCT00910637BayerGestodene/EE Patch

Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles

Start: May 2009Est. completion: Dec 20101,502 patients
Phase 3Completed
NCT00914693BayerEthinylestradiol/Gestodene

EU/LA Pearl Index Study - Transdermal Contraceptive Patch

Start: Apr 2009Est. completion: Sep 20111,694 patients
Phase 3Completed
NCT00819312BayerYAZ

YAZ, Oral Contraceptive Registration in China

Start: Dec 2008Est. completion: Jan 2011675 patients
Phase 3Completed
NCT00362479TevaDR-102

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

Start: Aug 2006Est. completion: Jul 20071,347 patients
Phase 3Completed
NCT00196326TevaDR-1011

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

Start: Jun 2005Est. completion: Jun 20072,235 patients
Phase 3Completed
NCT00206583BayerEV/DNG

Efficacy and Safety Study of an Oral Contraceptive in Healthy Females

Start: Mar 2005Est. completion: Jul 2007499 patients
Phase 3Completed
NCT00185367BayerEV/DNG

Comparative Cycle Control Europe

Start: Mar 2005Est. completion: Sep 2006798 patients
Phase 3Completed
NCT00185354BayerBAY86-5016, SH P00331F

FC Patch Comparator Study

Start: Nov 2004Est. completion: Apr 2006422 patients
Phase 3Completed
NCT00185289BayerEV/DNG

Study to Investigate Efficacy and Safety of a New Oral Contraceptive

Start: Apr 2004Est. completion: Jul 20061,392 patients
Phase 3Completed
NCT00185484BayerYAZ

Efficacy and Safety Oral Contraceptive Study

Start: Mar 2004Est. completion: Jan 20061,113 patients
Phase 3Completed
NCT00624130BayerYasmin 20

Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers

Start: Mar 2004Est. completion: Jun 2005453 patients
Phase 3Completed
NCT00220324BayerMinisiston

Pearl Index Study With Low Dose Combined Oral Contraceptive

Start: Feb 2004Est. completion: Nov 2005840 patients
Phase 3Completed
NCT00196352TevaLevonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

Start: May 2003Est. completion: Nov 2006320 patients
Phase 3Completed
NCT00245921PfizerLevonorgestrel 90 mg/Ethinyl Estradiol 20 mg

Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

Start: Feb 2003Est. completion: Oct 20052,000 patients
Phase 3Completed
NCT00236769Johnson & Johnsonnorelgestromin + ethinyl estradiol

A Study of Efficacy and Safety With the Transdermal Contraceptive System.

Start: Nov 1997Est. completion: Oct 19991,751 patients
Phase 3Completed
NCT00236782Johnson & Johnsonnorelgestromin + ethinyl estradiol

A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.

Start: Oct 1997Est. completion: Mar 19991,517 patients
Phase 3Completed
NCT00236795Johnson & Johnsonnorelgestromin + ethinyl estradiol

A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.

Start: Jan 1997Est. completion: Mar 19991,494 patients
Phase 3Completed
NCT02550977BayerGestodene/EE Patch

Russia/Ukraine Suppression of Ovarian Activity Study

Start: Sep 2015Est. completion: Aug 201691 patients
Phase 2Completed
NCT02490774BayerBAY1007626

To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development

Start: Jun 2015Est. completion: Jul 2016174 patients
Phase 2Terminated
NCT01204190BayerGestodene/EE Patch

Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.

Start: Sep 2010Est. completion: Aug 2011173 patients
Phase 2Completed
NCT00896571BayerEthinylestradiol/Gestogene

Transdermal Contraceptive Patch - Endometrial Effects Study

Start: Jul 2009Est. completion: Aug 201192 patients
Phase 2Completed
NCT00915915BayerEthinylestradiol/Gestodene

Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)

Start: Jun 2009Est. completion: Apr 2010108 patients
Phase 2Completed
NCT00873483BayerEthinylestradiol/Gestodene

US Ovulation Inhibition Study in Obese Women

Start: Apr 2009Est. completion: Mar 2010173 patients
Phase 2Completed
NCT00729404BayerEthinylestradiol/Gestodene

Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene

Start: Aug 2008Est. completion: Feb 200917 patients
Phase 2Terminated
NCT00631124BayerBAY86-4891

A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles

Start: Feb 2008Est. completion: Dec 2008103 patients
Phase 2Completed
NCT00185380BayerLevonorgestrel IUS

Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)

Start: Apr 2005Est. completion: Dec 2008742 patients
Phase 2Completed
NCT00185224BayerEV/DNG

Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive

Start: Mar 2005Est. completion: Mar 200658 patients
Phase 2Completed
NCT00805415BayerEV/DNG

Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens

Start: Mar 2003Est. completion: Feb 2004209 patients
Phase 2Completed
NCT04682353TevaTV-46046

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

Start: Dec 2020Est. completion: Jan 202360 patients
Phase 1Completed
NCT04291001Merck & Co.ENG implant

Ovarian Function With ENG Implant and UPA Use

Start: Sep 2020Est. completion: Jan 202440 patients
Phase 1Completed
NCT03700658TevaTV-46046

A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046

Start: Jan 2019Est. completion: Oct 202027 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

19 late-stage (Phase 3) programs — potential near-term approvals
9 companies competing in this space